(Re)programming Stem Cells for Drug Development

A medic by trade, Mark Kotter has always held a particular interest in neuroscience and stem cell research.

As founder and CEO of bit.bio, he's overseen the development of a unique approach to "reprogram" stem cells and change them into consistent and scalable disease-relevant cells, which can then be screened for potential therapeutics to help treat such diseases as Huntington's Alzheimer's, and ALS.

Hear about this revolutionary technology and how it works, what benefits it can provide researchers, and how it could very well shape the future of drug development.

Show Notes 

• Stem Cells for Drug Discovery 
• Building a Stable of Stem Cells 
• Conversations in Science With Disruptors Leading the Way 
• Neuroscience | Charles River 
• bit.bio 

Resources 

• https://www.bit.bio/news/focus-on-a-founder-with-mark-kotter-celebrating-10-years-of-community 
• https://www.criver.com/eureka/podcast/e28-building-the-building-blocks-of-life  
• https://www.criver.com/about-us/disruptors/meet-mark?region=3601 
• https://www.bit.bio/ 
• Stem Cells for Drug Discovery 
• Next Generation Reprogramming of Human iPSCs to Generate Disease-specific Glutamatergic Neurons Carrying HTT Gene for Huntington’s Disease Research and Drug Discovery
  https://www.criver.com/neuroscience-2021